Dr. Shaughnessy was formally Professor of Medicine and Biostatistics in the Department of Medicine at the University of Arkansas for Medical Sciences in Little Rock. He was also Director of the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics and ran the Division of Basic Sciences at the Myeloma Institute for Research and Therapy. Dr. Shaughnessy began his graduate studies in 1987 and received his Ph.D. from the University of Maryland in 1993. His dissertation research focused on the molecular-basis of plasma cell malignancies and was conducted at the National Cancer Institute’s Laboratory of Genetics with mentor and Lasker award winner, Dr. Michael Potter. In 1993, Dr. Shaughnessy took a postdoctoral fellowship with Copeland and Jenkins in the Mammalian Genetics Laboratory at NCI-Frederick. Using retroviral tagging to identify leukemia genes he cloned and characterized IL17RB and MRVI1, and together with Nakamura and Largaespada made seminal discoveries on the critical role of HOX, MEIS and NUP98 genes in myeloid leukemia. In 1996, Dr. Bart Barlogie recruited Dr. Shaughnessy back to research the genetics of multiple myeloma at the University of Arkansas for Medical Sciences. In late 1999, Donna and Donald Lambert funded the establishment of a laboratory dedicated to the use of microarray technology to study the molecular basis of Myeloma. In the decade from 2000 to 2010, Shaughnessy and Barlogie created the world’s largest clinco-genomic archive for multiple myeloma and in the process published over 150 peer-reviewed manuscripts and 27 patents. Dr. Shaughnessy has also delivered over 160 national and international invited lectures. In 2010, Shaughnessy, Barlogie, and Bennet Lebow, founded Signal Genetics to provide global access to the genomics-based diagnostic technology they developed, called MyPRS. Dr. Shaughnessy spent 2012 through 2015 working for and then consulting for Signal Genetics. In late 2015, Dr. Shaughnessy joined Dr. Barlogie at the Icahn School of Medicine at Mount Sinai to continue their collaborative research into the cause and cure of multiple myeloma. In early 2017, Signal Genetics sold MyPRS to Quest Diagnostics and merged with miRAGen to develop therapeutics for multiple myeloma based on Shaughnessy/Barlogie discoveries. Dr. Shaughnessy has published more than 180 peer-reviewed papers in journals such as Nature Genetics, Proceedings of the National Academy of Sciences, Cell, Cancer Cell, New England Journal of Medicine, FASEB Journal, and Blood. Dr. Shaughnessy currently commutes between New York City and Washington D.C. where he and his wife Kim reside with two of their four daughters in the Maryland suburbs.
Aging, Angiogenesis, Anti-Tumor Therapy, Antigen Presentation, Apoptosis/Cell Death, Autoimmunity, B Cells, Bioinformatics, Bone Biology, Bone Metabolism, Cancer, Cancer Genetics, Cell Adhesion, Cell Cycle, Cell Division, Cell Motility, Cell Transformation, Cellular Differentiation, Cellular Immunity, Chromatin, Cytokines, DNA Recombination, DNA Repair, DNA Replication, Developmental Biology, Drug Resistance, Embryology, Gene Discovery, Gene Expressions, Gene Regulation, Genetics, Genomics, Growth, Growth Factors and Receptors, Hematopoiesis, Immunoglobulin Genes, Immunology, Immunosuppression, Leukemia, Lymphocytes, Metastasis, Mitosis, Molecular Biology, Morphogenesis, Notch Signaling, Nucleus, Oncogenes, Osteoporosis, Pathology, RNA, Skeletal Biology, T Cells, Transcription Factors, Transcriptional Activation and Repression, Transplantation, Tumor Suppressor Genes, Tumorigenesis